Relugolix for Metastatic Hormone-sensitive Prostate Cancer with Impending Paraplegia.

Luteinizing hormone-releasing hormone agonists, used in advanced prostate cancer, can cause an initial testosterone surge and may inadequately suppress follicle-stimulating hormone, potentially promoting tumor growth. Injectable gonadotropin-releasing hormone (GnRH) antagonists avoid this surge but have drawbacks like injection-site reactions and monthly dosing. Relugolix, an oral GnRH antagonist, offers rapid testosterone suppression without flare and reduced cardiovascular risks.

The puzzle of high lifetime and low stabilization of HO˙: rationalization and prediction.

One of the most important puzzles in atmospheric chemistry is the long-lifetime of HO˙ in spite of its low-stabilization energy. In the present work, we have estimated the lifetime of HO˙ using classical dynamics simulations by coupling an available neural-network analytical potential energy surface with a chemical dynamics program. The simulation results clearly indicate that at room temperature, the lifetime of HO˙ can exceed 1 μs under collision-free conditions.

A Case of Gas Gangrene of the Right Foot: Clinical Presentation and Management.

Gas gangrene is a rare, life-threatening infection caused mainly by and other species, such as , , , and . Other microbial pathogens also reported to cause gas gangrene are and . It is fulminant and associated with high rates of morbidity and mortality, especially in patients with underlying comorbidities such as diabetes mellitus.